Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Edscharp who wrote (10133)	5/21/1999 10:13:00 AM
From: aknahow	Respond to of 17367

Agree but some of us thought the trial would end early. remember we were not told about the mortality requirement, which made it impossible,* to end early no matter how good Nuprex looked early on in the trial. Even at the very end with above 390 patients, XOMA did not end the trial without consultation with the FDA. *any company can end a trial whenever it wants for financial reasons. No one can force a company to keep going, if it decides it can't afford to do so. If anyone has not voted against management you can do so using the internet. Don't waste the opportunity to demonstrate that you believe shareholders deserve more open communication on the real issues.

To: Edscharp who wrote (10133)	5/21/1999 10:33:00 AM
From: aknahow	Read Replies (2) \| Respond to of 17367

Gonzalez and XOMA say there have been no leaks. I believe that XOMA is probably not the source of any leaks and actually believe that the P III results and data remain blinded and unleakable. But yet I think leaks occur. The only information of value is not the P III actual data. Partnership negotiations are also important pieces of information. Three entities are involved in this process. In total probably a minimum of 20 people know where any talks stand. Find it difficult to believe in the no leaks theory. Back to P III. So the actual data can be assumed not to be leaking. What about the fact that patients in the trial supposedly regained circulation in their extremities after the infusion of the drug/placebo under test? Do you think all those involved in treatment of these patients thought it was the placebo causing this reperfusion? Then obviously mortality was also low. Hundreds of people saw this sort of thing occur. Did none of them not check into XOMA? Can a large institution with the staff and capabilities check obituaries? The place of deaths and cause of death are matters of public record. So, IMO it is actually very probable someone knows a lot more than we do and part of it could be due to what is called leaks.